{"id":678779,"date":"2023-11-29T07:56:01","date_gmt":"2023-11-29T07:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=678779"},"modified":"2023-11-29T07:56:01","modified_gmt":"2023-11-29T07:56:01","slug":"projected-accelerated-growth-in-obsessive-compulsive-disorder-market-forecasted-for-20232032-analysis-by-delveinsight-companies-biohaven-pharmaceutical-alkermes-plctakeda-pharma-pfizer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/projected-accelerated-growth-in-obsessive-compulsive-disorder-market-forecasted-for-20232032-analysis-by-delveinsight-companies-biohaven-pharmaceutical-alkermes-plctakeda-pharma-pfizer_678779.html","title":{"rendered":"Projected Accelerated Growth in Obsessive Compulsive Disorder Market Forecasted for 2023-2032: Analysis by DelveInsight | Companies &#8211; Biohaven Pharmaceutical, Alkermes plc,Takeda Pharma, Pfizer"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1701178310.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Projected Accelerated Growth in Obsessive Compulsive Disorder Market Forecasted for 2023-2032: Analysis by DelveInsight | Companies - Biohaven Pharmaceutical, Alkermes plc,Takeda Pharma, Pfizer\" src=\"https:\/\/www.abnewswire.com\/uploads\/1701178310.jpeg\" alt=\"Projected Accelerated Growth in Obsessive Compulsive Disorder Market Forecasted for 2023-2032: Analysis by DelveInsight | Companies - Biohaven Pharmaceutical, Alkermes plc,Takeda Pharma, Pfizer\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Obsessive Compulsive Disorder Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s&nbsp;<strong>&ldquo;Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong>&nbsp;report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Obsessive Compulsive Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/obsessive-compulsive-disorder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Obsessive Compulsive Disorder Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Obsessive Compulsive Disorder Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Obsessive Compulsive Disorder market size is anticipated to grow with a significant&nbsp;<strong>CAGR<\/strong>&nbsp;during the study period&nbsp;<strong>(2019-2032)<\/strong><\/li>\n<li>According to the National Institute of Mental Health (n.d.),&nbsp;<strong>1% of US<\/strong>&nbsp;adult population members have OCD on any given year, and about half of these cases are severe<\/li>\n<li><strong>Key Obsessive Compulsive Disorder Companies:<\/strong>&nbsp;iohaven Pharmaceuticals, Inc., AbbVie, Biohaven Pharmaceuticals, Inc., AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Ortho-McNeil Janssen Scientific, Pfizer, and others<\/li>\n<li><strong>Key Obsessive Compulsive Disorder Therapies:<\/strong>&nbsp;Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim&reg;, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others<\/li>\n<li>The Obsessive Compulsive Disorder epidemiology based on gender analyzed that the occurrence of gender-specific cases of OCD is more in females than in males<\/li>\n<li>The Obsessive Compulsive Disorder market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obsessive Compulsive Disorder pipeline products will significantly revolutionize the Obsessive Compulsive Disorder market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Obsessive Compulsive Disorder Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Obsessive-compulsive disorder (OCD) is a widespread, persistent, and long-lasting mental illness in which a person experiences uncontrollable, recurrent thoughts (also known as &ldquo;obsessions&rdquo;) and\/or behaviours (sometimes known as &ldquo;compulsions&rdquo;) that they feel the need to repeat.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Obsessive Compulsive Disorder Market Report &ndash;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/obsessive-compulsive-disorder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/obsessive-compulsive-disorder-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Obsessive Compulsive Disorder Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Obsessive Compulsive Disorder Epidemiology Segmentation:<\/p>\n<p style=\"text-align: justify;\">The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Obsessive Compulsive Disorder<\/li>\n<li>Prevalent Cases of Obsessive Compulsive Disorder by severity<\/li>\n<li>Gender-specific Prevalence of Obsessive Compulsive Disorder<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Obsessive Compulsive Disorder<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/obsessive-compulsive-disorder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Obsessive Compulsive Disorder Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Obsessive Compulsive Disorder Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obsessive Compulsive Disorder market or expected to get launched during the study period. The analysis covers Obsessive Compulsive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Obsessive Compulsive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Obsessive Compulsive Disorder Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Troriluzole:<\/strong>&nbsp;Biohaven Pharmaceuticals, Inc.<\/li>\n<li><strong>Fluvoxamine maleate:<\/strong>&nbsp;AbbVie<\/li>\n<li><strong>BHV-4157:<\/strong>&nbsp;Biohaven Pharmaceuticals, Inc.<\/li>\n<li><strong>Troriluzole:<\/strong>&nbsp;Biohaven Pharmaceuticals, Inc.<\/li>\n<li><strong>Quetiapine:<\/strong>&nbsp;AstraZeneca<\/li>\n<li><strong>Reclaim&reg;:<\/strong>&nbsp;MedtronicNeuro<\/li>\n<li><strong>Bitopertin:<\/strong>&nbsp;Hoffmann-La Roche<\/li>\n<li><strong>topiramate:<\/strong>&nbsp;Ortho-McNeil Pharmaceutical<\/li>\n<li><strong>Escitalopram:<\/strong>&nbsp;Forest Laboratories<\/li>\n<li><strong>Duloxetine:<\/strong>&nbsp;Eli Lilly and Company<\/li>\n<li><strong>Topiramate:<\/strong>&nbsp;Janssen-Ortho Inc<\/li>\n<li><strong>Paliperidone:<\/strong>&nbsp;Ortho-McNeil Janssen Scientific<\/li>\n<li><strong>pregabalin:&nbsp;<\/strong>Pfizer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Obsessive Compulsive Disorder market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/obsessive-compulsive-disorder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Obsessive Compulsive Disorder Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Obsessive Compulsive Disorder Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong>&nbsp;7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Obsessive Compulsive Disorder Companies:<\/strong>&nbsp;iohaven Pharmaceuticals, Inc., AbbVie, Biohaven Pharmaceuticals, Inc., AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Ortho-McNeil Janssen Scientific, Pfizer, and others<\/li>\n<li><strong>Key Obsessive Compulsive Disorder Therapies:<\/strong>&nbsp;Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim&reg;, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others<\/li>\n<li><strong>Obsessive Compulsive Disorder Therapeutic Assessment:<\/strong>&nbsp;Obsessive Compulsive Disorder current marketed and Obsessive Compulsive Disorder emerging therapies<\/li>\n<li><strong>Obsessive Compulsive Disorder Market Dynamics:<\/strong>&nbsp;Obsessive Compulsive Disorder market drivers and Obsessive Compulsive Disorder market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp;SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Obsessive Compulsive Disorder Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Obsessive Compulsive Disorder Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Obsessive Compulsive Disorder companies working in the treatment market, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/obsessive-compulsive-disorder-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Obsessive Compulsive Disorder Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Obsessive Compulsive Disorder Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Obsessive Compulsive Disorder<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Obsessive Compulsive Disorder<\/p>\n<p style=\"text-align: justify;\">4. Obsessive Compulsive Disorder Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Obsessive Compulsive Disorder Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Obsessive Compulsive Disorder Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Obsessive Compulsive Disorder Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Obsessive Compulsive Disorder&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Obsessive Compulsive Disorder Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Obsessive Compulsive Disorder Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Obsessive Compulsive Disorder Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Obsessive Compulsive Disorder Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Obsessive Compulsive Disorder Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Obsessive Compulsive Disorder Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Obsessive Compulsive Disorder Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Obsessive Compulsive Disorder Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Obsessive Compulsive Disorder Appendix<\/p>\n<p style=\"text-align: justify;\">18. Obsessive Compulsive Disorder Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=projected-accelerated-growth-in-obsessive-compulsive-disorder-market-forecasted-for-20232032-analysis-by-delveinsight-companies-biohaven-pharmaceutical-alkermes-plctakeda-pharma-pfizer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=projected-accelerated-growth-in-obsessive-compulsive-disorder-market-forecasted-for-20232032-analysis-by-delveinsight-companies-biohaven-pharmaceutical-alkermes-plctakeda-pharma-pfizer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Obsessive Compulsive Disorder Market (Albany, USA) DelveInsight&rsquo;s&nbsp;&ldquo;Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2032&Prime;&nbsp;report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/projected-accelerated-growth-in-obsessive-compulsive-disorder-market-forecasted-for-20232032-analysis-by-delveinsight-companies-biohaven-pharmaceutical-alkermes-plctakeda-pharma-pfizer_678779.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-678779","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/678779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=678779"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/678779\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=678779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=678779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=678779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}